As Advair Sales Fall, GSK’s Witty Reminds Investors Launches Need Time
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s sales of Advair nose-dived 15% in the first quarter due to pricing pressure and loss of insurance coverage. New respiratory products like Breo Ellipta have yet to make a dent toward shoring up respiratory sales.
You may also be interested in...
With Anoro, GSK Takes A Two-Step Toward Bolstering Respiratory
FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.
Sarepta Files DMD Gene Therapy, Seeking An Accelerated Path To Market
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.
ArsenalBio Adds Genentech As A Partner While Embarking On Internal CAR-T Program
The start-up will secure $70m from Genentech, after closing a series B financing, while it moves its first CAR-T program into the clinic for ovarian cancer later this year.